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Owing to the inability of self-replacement by a damaged myocardium, alternative strategies to heart transplantation have been
exploredwithin the last decades and cardiac tissue engineering/regenerativemedicine is among the present challenges in biomedical
research. Hopefully, several studies witness the constant extension of the toolbox available to engineer a fully functional, contractile,
and robust cardiac tissue using different combinations of cells, template bioscaffolds, and biophysical stimuli obtained by the use of
specific bioreactors.Mechanical forces influence the growth and shape of every tissue in our body generating changes in intracellular
biochemistry and gene expression. That is why bioreactors play a central role in the task of regenerating a complex tissue such as
the myocardium. In the last fifteen years a large number of dynamic culture devices have been developed and many results have
been collected. The aim of this brief review is to resume in a single streamlined paper the state of the art in this field.
1. Introduction
Bioengineered tissue is a potential solution for the replace-
ment of a damaged failing heart [1, 2]. In this respect, the
ability to emulate in a cell culture the physical cues involved
in the physiological development of a normal cardiac tissue
is a key for a successful application of tissue engineering in
regenerative medicine. Although bioengineered tissues such
as skin [3] and bone [4] are already a clinical option available
to patients, cardiac muscle tissue engineering is a present
challenge in biomedical research—albeit several studies wit-
ness a definite advancement in this field [5].
“Cell therapy,” that is, the direct injection of cell suspen-
sions in damaged cardiac areas has a documented potential
for cardiovascular repair [6]. Obviously, which type of cells
has to be used to generate an artificial heart tissue represents
a relevant issue, since it heavily impacts the final properties
of a graft. As a matter of fact, cells should at least be
highly viable, able of electromechanical integration with
the resident healthy cardiomyocytes, and possibly histocom-
patible. In this respect, the effectiveness of grafting stem
cells (SCs) into a damaged heart is nowadays more than
just a proof of principle [7–10]. It is well established that
embryonic SCs (ESCs) are able to generate cardiomyocytes
[11]. However, ethical and technical issues (risk of teratoma
following transplantation of ESC-derived cardiomyocytes
[12]) limit their clinical potential. The ability to generate
induced pluripotent SCs (iPSCs) [13] provides an approach
for the generation of autologous grafts. Moreover iPSCs
appear able of cardiomyogenic differentiation [14]. Their
main limitations for the clinical use are the time requirement
for the reprogramming procedure and, again, the need to
ensure that they are nontumorigenic. Resident cardiac SCs
are another promising phenotype that can be isolated from
identifiable cardiac niches and expanded ex vivo [15]. How-
ever, the high invasiveness of the withdrawal technique limits
their clinical application. Thus, recently adult mesenchymal
SCs (MSCs) have been extensively investigated, aiming to
their use in biological constructs for cardiac repair, due to
the relative ease and safeness of their procurement—mainly
from bone marrow and adipose tissue—also in humans. [16–
18]. Irrespective of the phenotype, cell therapy is however
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Figure 1: Schematic description of the common features of bioreac-
tors for tissue engineering.
hampered by the poor survival of injected cells: in fact, most
of them die shortly after grafting into the injured heart where
hypoxia, nutrient deprivation, loss of survival signals, and
inflammation are all responsible for contributing to a hostile
environment [19–21]. Engineering a pseudotissue in vitro
for subsequent engraftment in vivo was thus proposed as
a more suitable approach than the direct cell injection. In
this case, a scaffold should provide a structured environment
with tissue-specific mechanical properties and the ability to
integrate with surrounding tissue [22, 23]. Biomaterials used
for scaffold fabrication include biological molecules (e.g.,
alginate, collagen, fibrin, and hyaluronan) and biomimetic
synthetic polymers (e.g., polylactic and polyglycolic acids
and their copolymers, polycaprolactone) where a specific
supramolecular architecture is designed to sustain the differ-
entiation and functional organization of the seeded cells [24–
31].
The appropriate elastic modulus and a 3D environment
of the scaffold are preferred to drive the differentiation of
SCs into cardiac muscle tissue [32–34]. Cell expansion and
differentiation in culture, to develop a cardiac pseudotissue
ex vivo, will take advantage of using a bioreactor, to guarantee
environmental conditions and biophysical parameters able to
induce, sustain and enhance the development of engineered
cardiac graft. Introduction of bioreactors in tissue engineer-
ing was driven by the need to apply defined culture regimes
[35] and they can be defined as any apparatus able to provide
in vitro a favorable physicochemical environment to promote
physiological conditions for cell/tissue growth. In a general
way, they share some common features, such as maintaining
the desired concentration of gases and nutrients in the culture
medium, establishing a uniform distribution of cells on a
3D scaffold, and exposing the developing tissue to physical
stimuli according to the functional requirements of the tissue
to be engineered (Figure 1) [36].
In the last decade, the bioreactor technology in the
field of cardiac tissue engineering evolved from very simple
apparatus, such as spinner flask/rotating vessel (Figure 2(a)),
to more complicated systems, such as perfusion bioreactors
(Figure 2(b)) and dynamic loading chambers (Figures 2(c)
and 2(d)). Older devices were intended for improving nutri-
ent and gas distribution by mixing media without providing
full control of culture parameters.These instruments became
more and more sophisticated in order to apply defined
physical stimuli [unidirectional or biaxial (cyclic) deforma-
tion, compression, stretch, perfusion, electrical force, etc.]
appropriate to act on cell differentiation. A number of distinct
configurations are nowadays available for specific purposes.
Since the specific feature of cardiac muscle is the coordinated
electromechanical coupling among its cells we here focus
on an update on bioreactors used for engineering cardiac
pseudotissue, reporting the approaches described in this field
to date.
2. Bioreactors for Cardiac Tissue Engineering
The application of specific physical stimuli in a tailored
bioreactor emerged as an appropriate strategy to obtain a
bioengineered cardiac tissue, where mechanotransduction
is known to play a significant role [37]. The initial evi-
dence of effectiveness of mechanostimulation protocols in
cardiac tissue engineering dates back to the second half
of the nineties, when Vandenburgh et al. [38] showed that
unidirectional mechanical stretch initiated in vitro a number
of morphological alterations in a confluent cardiomyocyte
population which were similar to those occurring during in
vivo heart growth. A few years later, culturing engineered
tissue undermixing ofmedium in a culture vessel was proven
to help induce 3D constructs with cardiac-specific structural
and electrophysiological properties [39, 40].
Since then a number of increasingly sophisticated
approaches followed, and the purpose of this review is their
listing according to the preferred approach endorsed for
the application of the mechanostimulation protocol, that is,
either the mechanical strain or the perfusion flow (see also
Table 1).
2.1. Mechanical Strain. Six days of unidirectional stretch of
engineered heart tissue (EHT)—made out of neonatal rat
or embryonic chick cardiomyocytes mixed in collagen I—in
a custom-made device improved their cellular organization
and increased atrial natriuretic factor (ANF) mRNA and
𝛼-sarcomeric actin compared to unstretched controls [41].
The force of contraction of this EHT was up to fourfold
higher after mechanical stimulation and the protocol was
proposed as an in vitro model allowing morphological,
molecular, and functional consequences of stretch to be stud-
ied under defined conditions. This same German research
group developed shortly after [43] an improved technique to
obtain circular EHT resulting in better technical feasibility,
tissue homogeneity, and cardiomyocyte differentiation. After
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Figure 2: Schematic description of significant physical stimuli applied to cells growing in a bioreactor. A spinner flask/rotating vessel (a)
improves nutrient and gas distribution by mixing culture media. Perfusion-based bioreactors (b) promote cell proliferation and matrix
production via pulsatile flow and shear forces. Dynamic loading chambers (c, d) are intended to apply defined mechanical forces such as
(cyclic) unidirectional (c) or biaxial (d) deformation to generate a strain.
seven days of unidirectional cyclic stretch (10%; 2Hz), the
EHT displayed structural and functional features of a native
differentiatedmyocardium andwere proposed as a promising
material for in vitro studies of cardiac function and tissue
replacement therapy.
In the same year Akhyari et al. [42] proved that amechan-
ical stretch regimen—applied via the Biostretch apparatus
(ICCT Technologies, Markham, ON, Canada) presented by
Liu et al. [65] (mechanical properties and remodeling of
hybrid cardiac constructs made from heart cells, fibrin,
and a biodegradable, elastomeric knitted fabric were tested
using the same apparatus by Boublik et al. in 2005 [46]) to
human heart cells that were seeded on a 3D gelatin scaffold
(Gelfoam sponge, Pharmacia & Upjohn Co., Kalamazoo, MI,
USA)—improves the formation and enhances the strength
of a bioengineered muscle graft. Dynamic stimulation of
cells/gelatine constructs during 14 days (80 cycles/min with
a 20% deformation of the initial length) generated a marked
increase in cell proliferation, improved spatial cell distribu-
tion throughout the scaffold, and markedly increased the
total amount of newly synthesized collagenmatrix with fibres
aligned in parallel to the axis of stress.
Iijima et al. [44] showed that mechanical load on skeletal
muscle-derived cells is important for their transdifferentia-
tion into the cardiac phenotype since passive cyclic stretch
(60 cycles/min) of skeletal muscle-derived cells cocultured
on silicone dishes with cardiomyocytes entirely restored the
inhibition of their spontaneous beating produced with 5𝜇M
nifedipine.
At this stage the application of a mechanostimulation
protocol on terminally differentiated cells entered the age of
majority: Zimmermann et al. [66, 67] provided the evidence
that contractile cardiac tissue grafts, generated with the aid of
mechanical strain in vitro, can survive after implantation and
can support contractile function of infarcted rat hearts.
Since stem cells have entered the arena of regenera-
tive medicine, the use of mechanostimulation protocols to
address their cardiac differentiation was witnessed in several
scientific reports.
In 2008, Gwak et al. [50] investigated whether cyclic
mechanical strain promotes cardiomyogenesis in mouse
6 BioMed Research International
embryonic stem cell (ESCs) seeded on the elastic polymer
poly(lactide-co-caprolactone) (PLCL). Mechanical load was
applied in a custom-made bioreactor, previously described
by Kim and Mooney [68]. The scaffolds were subjected to
cyclic strain (10%; 1Hz) in a standard incubator for 2 weeks.
Mechanical load promoted cardiac-specific gene expression
and tests in vivo showed a significant increase of grafting
efficiency and the cardiomyogenic potential of the implanted
cells.
In the same year, Shimko and Claycomb [51] used a
bioreactor where ring-shaped constructs were stretched via
a computer-controlled mechanism to explore the effects
of long-term mechanical loading on mouse ESCs-derived
cardiomyocytes. The cells, embedded in a 3D gelatinous
scaffold (collagen type I and fibronectin), underwent cyclical
mechanical stimulation (10%; 1, 2, and 3Hz) for 3 days.
This study demonstrated that ESCs-derived cardiomyocytes
are actively responding to physical cues from the environ-
ment: 𝛼-cardiac actin, 𝛼-skeletal actin, 𝛼-myosin heavy chain
(MHC), and 𝛽-MHC were all upregulated at 3Hz.
In 2009, Ge et al. [52] investigated cardiomyocyte differ-
entiation potential of rat bone marrow-mesenchymal stem
cells (BM-MSCs) treating these cells by applying 4% strain
at 1Hz. Biaxial mechanical stress, provided with a custom
device previously described by Banes et al. [69], induced in
BM-MSCs the expression of cardiomyocyte-specific genes
including 𝛼-actin, connexin 43, 𝛼-MHC, and troponin I.
During the most recent years, the application of mechan-
ical cyclic strain to 2D cell cultures was often obtained using
the Flexcell Strain Unit (Flexcell Int., Hillsborough, NC,
USA), a commercial device where vacuum pressure applied
to flexible-bottomed silicone culture plates produces uniaxial
or biaxial deformation.
In 2010, Salameh et al. [55] examined with this device
whether cyclic mechanical stretch can affect localization of
gap junctions with regard to the cell axis. Neonatal rat
cardiomyocytes seeded on gelatin-coated membranes were
stimulated (1Hz; 0, 10, and 20% elongation) for 24 or 48
hours. Cyclic mechanical stretch (24 hour, 10%) induced
elongation of the cardiomyocytes and orientation toward
the stretch direction. Moreover, the distribution of connexin
43 and N-cadherin was accentuated at the cell poles. A
significant increase in the transcription factors activator
protein 1 and cAMP response element-binding protein was
also scored.
In 2011, Maul et al. [60] used the Flexcell Unit for the
systematic analysis of mechanical stimulation on SCs differ-
entiation. Experiments were conducted using subconfluent
MSCs for 5 days and demonstrated significant effects on
morphology and proliferation, defining thresholds of cyclic
stretch that potentiate (smooth) muscle protein expression.
This systematic examination of the effects of mechanical
stimulation on MSCs has implications for the understanding
of SCs biology, as well as potential bioreactor designs for
tissue engineering and cell therapy applications.
In the same year, Tulloch et al. [61] used human
ESCs and induced pluripotent SC-derived cardiomyocytes
in a 3-dimensional collagen matrix, to show that uniaxial
mechanical stress conditioning—imparted with the Flexcell
Unit—promotes a twofold increase of cardiomyocyte pro-
liferation, matrix fiber alignment, and enhanced myofibril-
logenesis and sarcomeric banding. Addition of endothelial
cells enhanced cardiomyocyte proliferation, and addition of
stromal supporting cells enhanced formation of vessel-like
structures. These optimized human cardiac tissue constructs
generate Starling curves, developing active force in response
to increased resting length. Moreover, when transplanted
onto hearts of athymic rats, the humanmyocardium survived
and formed grafts closely apposed to host myocardium
and containing human microvessels perfused by the host
coronary circulation.The authors concluded that mechanical
load and vascular cell coculture control cardiomyocyte prolif-
eration, hypertrophy, and architecture of engineered human
myocardium. Such constructs were proposed for studying
human cardiac development as well as for regenerative
therapy.
To test the mechanical integrity and functionality of
SCs engineered constructs prior to implantation, Hollweck
et al. [57] proposed in 2011 a pulsatile bioreactor mim-
icking myocardial contraction. Mesenchymal stem cells
derived from umbilical cord tissue (UCMSC) were colonized
on titanium-coated polytetrafluorethylene (PFTE) scaffolds
and underwent sinusoidal pulsation. Experiments to deter-
mine the adherence rate and morphology of UCMSC after
mechanical loading showed an almost confluent cellular
coating without damage on the cell surface and the bioreactor
appeared an adequate tool for themechanical stress of seeded
scaffolds in order to precondition cardiac tissue engineered
constructs in vitro.
All this evidence in the literature demonstrates the effect
of cyclic mechanical stretch in maintaining, or addressing,
a muscle phenotype. However, all the presented results
were obtained using technical approaches useful for the
experimental collection of proofs of principle but unlikely
suitable for application in clinical protocols for regenerative
medicine. Focusing on this issue, our group [62] designed
a reliable innovative bioreactor, acting as a stand-alone cell
culture incubator, easy to operate and effective in addressing
rat MSCs seeded onto a 3D bioreabsorbable scaffold, toward
a muscle phenotype via the transfer of a controlled and
highly reproducible cyclic deformation. Electronmicroscopy,
immunohistochemistry, and biochemical analysis of the
pseudotissue constructs obtained after 1 week of cyclic
mechanical stretch (10%; 1.6Hz) showed cell multilayer
organization and invasion of the 3D mesh of the scaffold.
In addition they expressed typical markers of the muscle
phenotype. This device is thus proposed as a prototypal
instrument to obtain, using good manufacturing procedures,
pseudotissue constructs to test in cardiovascular regenerative
medicine.
2.2. Perfusion Bioreactors. Bioreactors used in cardiac tissue
regeneration include devices where a mechanical load is
transferred to the cells by culture medium routed (pulsatile
flow, shear stress) through the construct with a perfusion
loop.
In 2004, Radisic et al. [45] designed an in vitro culture
system maintaining efficient oxygen supply to neonatal rat
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cardiomyocytes suspended in Matrigel and cultured on col-
lagen sponges for 7 days with interstitial flow of medium.
Constructs were assessed at timed intervals with respect
to cell number, distribution, viability, metabolic activity,
cell cycle, presence of contractile proteins (sarcomeric 𝛼-
actin, troponin I, and tropomyosin), and contractile function
in response to electrical stimulation. Perfusion resulted in
higher cell viability and, in response to electrical stimulation,
perfused constructs contracted synchronously and had a
lower excitation threshold than controls.
A microbioreactor array, fabricated using soft lithogra-
phy and containing twelve independent microbioreactors
perfused with culture medium, was presented by Figallo
et al. [48] in 2007. This device enabled cultivation of cells
either attached to substrates or encapsulated in hydrogels,
at variable levels of hydrodynamic shear, and with auto-
mated image analysis of the expression of cell differentiation
markers. This configuration was validated using primary
rat cardiomyocytes and human ESCs evaluating correlations
between the expression of smooth muscle actin and cell
density for three different flow configurations.
Brown et al. [49] used a perfusion bioreactor suggesting
that the provision of pulsatile interstitial medium flow to
an engineered cardiac patch would result in enhanced tissue
assembly by way of mechanical conditioning and improved
mass transport. Cardiac patches, obtained by the seeding of
neonatal rat cardiomyocytes onto Ultrafoam collagen hemo-
stat discs, were cultured for 5 days subjected to two different
overall flow rates (1.50mL/min or 0.32mL/min) at 1Hz.
The data reported in this study show that cultivation under
pulsatile flow has beneficial effects on contractile properties
and promotes cell hypertrophy.
In 2009, Hosseinkhani et al. [54] combined micro-
and nanoscale technologies to fabricate a 3D collagen-poly
(glycolic acid) (PGA) cell substrate for tissue engineering
purposes where rat cardiac SCs (CSCs) were seeded and
perfused to give a constant laminar flow of medium into
the cell constructs to enhance their attachment and prolif-
eration. Results demonstrated that this perfusion bioreactor
improved the proliferation of CSCs in vitro compared with
standard culture methods.
More recently, Kenar et al. [58] designed and developed a
myocardial 3D patch formed by a microfibrous mat housing
MSCs from human umbilical cord matrix (Wharton’s Jelly)
aligned in parallel to each other as they are in native
myocardium. The 3D construct was dynamically cultured in
a bioreactor by transiently perfusing cell medium through
the macroporous tubing of the mat. After two weeks in
the bioreactor, perfused cultures demonstrated enhanced cell
viability, uniform cell distribution, and alignment due to
nutrient provision from inside the 3D structure.
This brief listing of flow-controlling devices for tissue
cardiac engineering ends mentioning that in the same
manuscript published by Maul et al. [60] in 2011, in addition
to the use of the Flexcell Unit for the systematic analysis of
mechanical stimulation on SCs differentiation (see above),
the authors also evaluated on MSCs the impact of laminar
shear stress—applied via the Streamer shear stress Flexcell
device—that increased endothelial cell protein expression in
a cell-contact-dependent manner.
2.3. Hybrid Bioreactors. In a limited number of cases, the
research in the field proposed hybrid devices, where more
than a single type of mechanical stress is applied to cultured
cells addressed toward the cardiac phenotype. As an example,
electric and mechanical stimuli were occasionally applied to
SCs on the hypothesis that the coupling of these stimulimight
produce a synergy for their differentiation process.
Feng et al. [47] presented the first bioreactor systemwhere
cardiomyocytes from rat embryos were seeded on collagen-
coated silicon membranes and cultured up to 4 days under
electromechanical stimulation. Their results emphasized the
importance of electrotensile forces on the augmentation of
the contractile force in a “cardiac tissue equivalent.”
Barash et al. [53] used a custom-made electrical stim-
ulator, integrated into a perfusion bioreactor originally
described in 2006 by Dvir et al. [70], with the purpose of
producing thick and functional cardiac patches. Rat ventric-
ular cardiomyocytes were seeded on porous alginate scaffolds
and subjected to a homogenous fluid flow regime with
electrical stimulation. Results showed that the cultivation in
this bioreactor for 4 days under perfusion and continuous
electrical stimulus promoted cell elongation and striation.
Immunostaining and western blotting analysis demonstrated
that the expression level of connexin 43 was enhanced.
In 2011, Galie and Stegemann [56] validated a device
where simultaneousmechanical and fluidic stress was applied
to a 3D cell construct. Cardiac fibroblasts were suspended
in a collagen type I gel to obtain a 3D cell construct and
subjected to cyclic strain (5%; 1Hz) and interstitial flow
(10mL/min). Cell viability was certified after 5 days in
bioreactor under the application of these stimuli. This simple
bioreactor system was thus proposed to model tissues such
as the myocardium, which experiences interstitial fluid flow
from perfusion through the extracellular matrix as well as
cyclic strain from the systole—diastole cycle of the heart.
Kensah et al. [59] proposed in 2011 a multimodal bioreac-
tor for mechanical stimulation and real-time direct measure-
ment of contraction forces under continuous sterile culture
conditions. The bioreactor’s transparent cultivation chamber
allows for microscopic assessment of tissue development.
Additional functions include electric pacing of tissues, as
well as the possibility to perfuse the central cultivation
chamber allowing for continuous medium exchange and/or
controlled addition of pharmacologically active agents. A
functional bioartificial cardiac tissue was generated from
rat cardiomyocytes in the bioreactor, where cyclic stretch
induced cardiomyocyte hypertrophy and moderate increase
in systolic force. Thus, this bioreactor is proposed as a tool
for monitoring tissue development, and ultimately, optimiz-
ing SCs-based tissue replacement strategies in regenerative
medicine.
Recently, Maidhof et al. [63] asserted that fixing the cell
constructs in place for perfusion culture is a severe limitation.
Thus, they proposed the design of a bioreactor to deliver
simultaneous culture medium perfusion and electrical stim-
ulation during the culture of engineered cardiac constructs
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free of external fixation. Neonatal rat heart cells were seeded
onto channeled microporous elastomer poly(glycerol seba-
cate) (PGS) scaffolds and the neoformed pseudotissues were
stimulated in the bioreactor for eight days. This dynamic
culture protocol demonstrated significant improvement of
DNA contents in the cell constructs, homogeneous cell
distribution throughout the scaffold thickness, enhancement
of cardiac protein expression (such as cardiac troponin T
and connexin 43) and better cell morphology and overall
tissue organization than observed in control group. Although
cardiac cells did not form uniformly interconnected tissue
after eight days of stimulation in the bioreactor, the results
obtained in this study indicated that simultaneous perfusion
and electric stimulation enhanced the development of engi-
neered cardiac tissue. Thus, this device could be a relevant
tool for cardiac repair in vitro studies and to understand the
effective presence of a synergistic effect between perfusion
and electric stimuli.
Usually, compression stimulus was extensively used for
bone and cartilage tissue engineering [71–73]; however the
favourable effect of mechanical compression was successfully
certified in a cardiac tissue engineering protocol.
In particular, Shachar et al. [64] investigated how
mechanical compression stimulus, combined with fluid shear
stress provided by medium perfusion, could lead to the
formation of a cardiac muscle tissue in vitro. Neonatal rat
cardiac cells were seeded in Arginine-Glycine-Aspartate-
(RGD-) attached alginate scaffolds and cultivated for 4 days
in a bioreactor for compression and fluid flow stimulation.
Two types of compression—intermittent (daily short-term
30 minutes) and continuous—were investigated. Upon appli-
cation of the “intermittent compression” protocol, western
blot showed enhancement of connexin 43, 𝛼-actinin, and N-
cadherin expression.
3. Conclusions
Bioreactors appear as a key factor for a successful appli-
cation of tissue engineering principles in cardiac regener-
ative medicine, where state-of-the-art mechanostimulation
protocols have definitely proven to control cell proliferation,
differentiation, and electrical coupling in engineered 3D
cardiac tissue. A take-home message from this review of the
current literature is that perfusion-based bioreactors are to
be preferred when, for example, the cell function of interest
is electively activated by shear stress, such as in the case
of endothelial progenitor cells; when hydrogel/non-elastic
scaffolds—which cannot be stretched bymechanical forces—
are in use; or when scaffold nutrient diffusion has to be
increased by a sustained flow. On the other hand, bioreactors
producing mechanical deformation are more suitable with
an elastomeric scaffold, where a coupled electromechanical
stimulation appears effective in promoting elongation, stria-
tion, and acquisition of contractile force by the stretched cells.
Another issue emerging here is that the translation of
these models into clinical products is not just around the
corner. Rather than a scientific challenge, regulatory and
commercial issues slowdown the pace. Identifying a roadmap
to drive this transition is an integral part of this challenge
[74] where the compliance with regulatory guidelines and a
robust and cost-effective approach have to match the already
available encouraging proofs of principle. Governmental
agencies in healthcare and stakeholders, togetherwith clinical
research societies and ethics committees, are now responsible
for releasing guidelines and resources for the advancement
expected by patients.
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